IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization.

Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.

Key Stats

• Today's Range: $26.84 to $28.39
• 50-Day Range: $22.41 to $27.64
• 52-Week Range: $13.45 to $32.67
• Volume: 668,204 shs
• Average Volume: 1.39 million shs
• Market Capitalization: $2.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.36
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 84% of companies evaluated by MarketBeat, and ranked 144th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 14 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

IDEAYA Biosciences has a consensus price target of $43.36, representing about 57.7% upside from its current price of $27.49.

Amount of Analyst Coverage

IDEAYA Biosciences has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.73% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 6.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

11.73% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 6.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

IDEAYA Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for IDEAYA Biosciences this week, compared to 7 articles on an average week.

Search Interest

Only 3 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

5 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDYA Stock Analysis - Frequently Asked Questions

How have IDYA shares performed this year?

IDEAYA Biosciences' stock was trading at $25.70 at the beginning of the year. Since then, IDYA shares have increased by 7.0% and is now trading at $27.49.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.03. The company's revenue was up NaN% on a year-over-year basis.

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $43.36
• High Price Target: $74.00
• Low Price Target: $25.00
• Potential Upside/Downside: +57.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.72
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$274.48 million
• Net Margins: N/A
• Pretax Margin: -4,740.03%
• Return on Equity: -31.42%
• Return on Assets: -29.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.39
• Quick Ratio: 12.39

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 344.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.25 per share
• Price / Book: 2.24

Miscellaneous

• Outstanding Shares: 87,640,000
• Free Float: 85,453,000
• Market Cap: $2.41 billion
• Optionable: Optionable
• Beta: 0.14